About Seikagaku
Seikagaku is a publicly listed company based in Tokyo (Japan) founded in 1996. Therapies for bone and ophthalmic disorders are developed. The company has 1,070 employees. Seikagaku has completed 1 acquisition, including Dalton Pharma Services. Its chief executive, as recorded, is Takeshi Mizutani. Its website seikagaku.co.jp draws about 15 thousand monthly visits. Its focus areas include Life Sciences, Orthopedics, Drugs and Diversified.
Company details
Seikagaku was founded in 1996 and is headquartered in Tokyo, Japan. Focus is placed on the biotechnology sector, where enzyme-based therapies for bone and ophthalmic conditions are developed. The lead product, SI-6603 (Condoliase), an enzyme designed to degrade glycosaminoglycans, is under investigation for lumbar disc herniation treatment. Phase III clinical trials are currently ongoing for this candidate. Operations center on advancing these specialized medical interventions.
- Headquarters Tokyo, Japan
- Employees 1,070
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website seikagaku.co.jp/ja/index.html
- Social LinkedIn
- Legal Name Seikagaku Corporation
- Annual Revenue$229.78 M (USD)-6.93as on Mar 31, 2026
- Net Profit$9.22 M (USD)21.33as on Mar 31, 2026
- EBITDA$9.4 M (USD)-54.79as on Mar 31, 2026
- Employee Count1,070
- Investments & Acquisitions
People of Seikagaku
2 people are tracked at Seikagaku (2 in leadership); the tracked headcount is 1,070.
| Name | Role | Group |
|---|---|---|
Takeshi Mizutani | CEO | Leadership |
Ken Mizutani | President & CEO | Leadership |
Complete people profiles for Seikagaku
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Seikagaku
Seikagaku is a publicly listed company on the TSE with ticker symbol 4548 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Mar 2004
- Listed onTSE: 4548
- Listed entitySeikagaku Corporation
- Exchange sectorHealth technology
- ISINJP3414000004
- Share price575.00 JPY (-1.54% on the day) · 2026-10-14
- Market capitalisation32,847,850,189.00 JPY
- Price to earnings18.9
- EPS (diluted, trailing year)30.44 JPY
- Dividend yield4.41%
- Volume (last session)176,300
Financials of Seikagaku
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 36.65B JPY | 1.47B JPY | 1.50B JPY |
| 2024 | 39.37B JPY | 1.21B JPY | 3.33B JPY |
| 2023 | 36.21B JPY | 2.19B JPY | 2.10B JPY |
| 2022 | 33.46B JPY | 2.24B JPY | 3.44B JPY |
| 2021 | 34.85B JPY | 3.73B JPY | 5.54B JPY |
Detailed financial statements for Seikagaku
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Seikagaku
Seikagaku has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Dalton Pharma Services.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Integrated drug discovery, development, and manufacturing services are provided worldwide. | dalton.com | Toronto, Canada | 1986 | Apr 2020 | •••• |
Complete acquisition details for Seikagaku
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Seikagaku
3 dated milestones of Seikagaku across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Seikagaku is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Dalton Pharma Services.
Web traffic of Seikagaku
The website of Seikagaku (seikagaku.co.jp) receives about 15.2K visits a month and ranks #1,854,288 among all websites worldwide, #2,533 in Biotechnology and Pharmaceuticals.
- Monthly visits15.2K
▲ 26.8% vs previous month
- Unique visitors6.3K
per month
- Global rank#1,854,288
among all websites
- Category rank#2,533
Health · Biotechnology and Pharmaceuticals
- Bounce rate55%
- Pages per visit2.0
- Average visit1 min 00 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Seikagaku. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
e-kansetsu.jp | e-kansetsu.jp | 100% | – | ||
| adragos-pharma.com | 96% | 37.7K | #765,754 | View details | |
| nebiolab.com | 95% | 20.8K | #944,903 | View details | |
| canbas.co.jp | 94% | 28.2K | #1,124,423 | View details | |
| bioagilytix.com | 91% | 41.6K | #919,146 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Seikagaku
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Seikagaku
Complete news archive for Seikagaku
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seikagaku
Seikagaku was founded in 1996.
Seikagaku is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Takeshi Mizutani is the CEO of Seikagaku, as recorded in our data.
Seikagaku has 1,070 employees.
Annual revenue of Seikagaku is $229.78M as on Mar 31, 2026.
Seikagaku was founded in 1996 and is headquartered in Tokyo, Japan. Focus is placed on the biotechnology sector, where enzyme-based therapies for bone and ophthalmic conditions are developed. The lead product, SI-6603 (Condoliase), an enzyme designed to degrade glycosaminoglycans, is under investigation for lumbar disc herniation treatment. Phase III clinical trials are currently ongoing for this candidate. Operations center on advancing these specialized medical interventions.
Yes, Seikagaku is publicly traded on TSE under the ticker symbol 4548.
Seikagaku has made 1 acquisition, including Dalton Pharma Services.